{"doi":"10.1007/s00296-024-05536-1","title":"Exploring 5-year changes in general and skin health-related quality of life in psoriatic arthritis patients","abstract":null,"journal":"Rheumatology International","year":2024,"id":603408,"datarank":0.20794415416798362,"base_score":1.3862943611198906,"endowment":1.3862943611198906,"self_citation_contribution":0.20794415416798362,"citation_network_contribution":0.0,"self_endowment_contribution":0.20794415416798362,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":3,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":900008,"name":"Brigitte Michelsen","orcid":"0000-0003-0103-2840","position":1,"is_corresponding":false},{"id":1547903,"name":"Katarzyna Łosińska","orcid":"0000-0003-2801-6584","position":2,"is_corresponding":false},{"id":55640,"name":"Arthur Kavanaugh","orcid":"0000-0001-6942-5830","position":3,"is_corresponding":false},{"id":1547905,"name":"Mariusz Korkosz","orcid":"0000-0002-1749-9739","position":4,"is_corresponding":false},{"id":1547907,"name":"Glenn Haugeberg","orcid":"0000-0002-9279-5191","position":5,"is_corresponding":false},{"id":1547900,"name":"Mateusz Wilk","orcid":"0000-0001-7967-0880","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Exploring 5-year changes in general and skin health-related quality of life in psoriatic arthritis patients","abstract":"Psoriatic arthritis (PsA) carries a severe disease burden, often leading to deterioration of health-related quality of life (HRQoL). Different comorbidities that are relatively prevalent in PsA are also responsible for compromised HRQoL. To assess real-world data of a 5-year follow-up cohort of PsA patients, focusing on changes in general HRQoL, skin HRQoL, and comorbidities. In this prospective observational study, 114 outpatients diagnosed with PsA were examined at baseline and after 5 years. Data collection included demographics, clinical disease activity measures, and patient-reported outcome measures (PROMs). General HRQoL was assessed with a 15D instrument, and skin HRQoL was assessed with the Dermatology Life Quality Index (DLQI). During the 5-year follow-up, no significant deterioration in HRQoL assessed by 15D (23.53 vs. 23.08, p = 0.85) and DLQI (3.48 vs. 2.68, p = 0.07) was observed. There was no observed decline in other PROMs. The mean total number of comorbidities increased (1.13 vs. 1.39, p < 0.01). A significant improvement in disease activity measures, including 66/68 swollen/tender joint count, Disease Activity Index for Psoriatic Arthritis (all p < 0.01), and Psoriatic Arthritis Severity Index (p = 0.04) was seen. A higher proportion of patients at 5 years were treated with b/tsDMARDs (37.7% vs. 46.5%, p = 0.03). Despite an increased number of comorbidities over 5 years, our PsA cohort showed no decline in HRQoL. This can be attributed to the widespread adoption of modern treatments, leading to improved disease control and the preservation of baseline HRQoL.","is_dataset_classified":null,"base_score":1.3862943611198906,"endowment":1.3862943611198906,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"38319377","pmcid":null,"openalex_id":"https://openalex.org/W4391563388","authors":[],"funders":[{"funder_name":"Pfizer","grant_id":"Unrestricted Research Grant number 5714134","title":null}],"total_grants":1,"fwci":0.995,"citation_percentile":0.73678215,"influential_citations":0,"citation_trend":[{"year":2024,"count":1},{"year":2025,"count":1},{"year":2026,"count":1}],"oa_status":"green","license":"cc-by-nc-nd","oa_locations":[{"url":"https://ruj.uj.edu.pl/handle/item/330488","host_type":"repository"},{"url":"https://ruj.uj.edu.pl/handle/item/330488","host_type":"repository"},{"url":"https://link.springer.com/content/pdf/10.1007/s00296-024-05536-1.pdf","host_type":"publisher"},{"url":"https://link.springer.com/article/10.1007/s00296-024-05536-1/fulltext.html","host_type":"publisher"},{"url":"https://doi.org/10.1007/s00296-024-05536-1","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/38319377","host_type":"repository"}],"fields_of_study":["Spondyloarthritis Studies and Treatments","Psoriasis: Treatment and Pathogenesis","Autoimmune and Inflammatory Disorders Research","Humans","Arthritis, Psoriatic","Quality of Life","Skin","Comorbidity","Cost of Illness","Severity of Illness Index"],"mesh_terms":["Humans","Quality of Life","Severity of Illness Index","Skin","Arthritis, Psoriatic","Comorbidity","Cost of Illness"],"keywords":["Medicine","Psoriatic arthritis","Internal medicine","Quality of life (healthcare)","Dermatology Life Quality Index","Cohort","Psoriasis","Comorbidity","Cohort study","Observational study","Severity of illness","Rheumatology","Disease","Physical therapy","Dermatology","Quality of life","Follow-up Study","Comorbidities","Biological Therapy"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Zero hunger"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-29T21:52:26.026662Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}